Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
April 2, 2018
Revance Therapeutics Expands Commercialization Team to Gear Up for Product Launch of RT002 Injectable
March 26, 2018
Revance to Host Investor Day on April 19, 2018
March 20, 2018
Revance to Participate in the Needham Healthcare Conference
March 6, 2018
Revance to Participate in Upcoming Investor Conferences
February 28, 2018
Revance Releases Fourth Quarter and Full Year 2017 Results
February 28, 2018
Mylan to Bring a Biosimilar of BOTOX to the Market Through a Collaboration and License agreement with Revance Therapeutics
February 22, 2018
Revance Therapeutics to Release Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 28, 2018
February 14, 2018
Revance to Participate in the RBC Capital Markets 2018 Global Healthcare Conference
February 1, 2018
Pivotal SAKURA Phase 3 Clinical Data to be Presented at IMCAS World Congress 2018
January 8, 2018
Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis
Displaying 161 - 170 of 288